Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 14-09-2022 | Escherichia Coli | Brief Report

Molecular analysis of OXA-48-producing Escherichia coli in Switzerland from 2019 to 2020

Authors: Jacqueline Findlay, Vincent Perreten, Laurent Poirel, Patrice Nordmann

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2022

Abstract

OXA-48-type ß-lactamases are the most prevalent carbapenemase-type in Enterobacterales in Switzerland, predominantly found in Escherichia coli and Klebsiella pneumoniae. Bacteria-producing OXA-48-type enzymes are endemic in some parts of the world, including Europe and North Africa, and are a frequent cause of nosocomial infections. Despite the emergence of numerous OXA-48-type variants, the original variant, OXA-48, remains the most prevalent in E. coli. This study describes the epidemiology of OXA-48-producing E. coli isolates submitted to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) between January 2019 and December 2020.

Available only for authorised users

Antimicrobial Resistance Collaborators (2019) Global burden of antimicrobial resistance in 2019: a systematic analysis. Lancet 10325:629–655

Poirel L, Héritier C, Tolün V, Nordmann P (2004) Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15–22CrossRef

Pitout JDD, Peirano G, Kock MM, Strydom K-A, Matsumura Y (2019) The global ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev 33:e00102-e119CrossRef

Mairi A, Pantel A, Sotto A, Lavigne J-P, Touati A (2018) OXA-48-like carbapenemases producing Enterobacteriaceae in different niches. Eur J Clin Microbiol Infect Dis 37:587–604CrossRef

Beta-lactamase database. http://bldb.eu/. Accessed 12 June 2022

Bakthavatchalam YD, Anandan S, Veeraraghavan B (2016) Laboratory detection and clinical implication of oxacillinase-48 like carbapenemases: the hidden threat. J Glob Infect Dis 8:41–50CrossRef

Poirel L, Castanheira M, Carrër A, Rodriguez CP, Jones RN, Smayevsky J, Nordmann P (2011) OXA-163, an OXA-48-related class D β-lactamase with extended activity toward expanded-spectrum cephalosporins. Antimicrob Agents Chemother 55:2546–2551CrossRef

Dortet L, Oueslati S, Jeannot K, Tandé D, Naas T, Nordmann P (2015) Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 59:3823–3828CrossRef

Ramette A, Gasser M, Nordmann P, Zbinden Z, Schrenzel J, Perisa D, Kronenberg K (2021) Temporal and regional incidence of carbapenemase-producing Enterobacterales, Switzerland, 2013 to 2018. Euro Surveill 26(15):1900760

10.

Turton JF, Doumith M, Hopkins KL, Perry C, Meunier D, Woodford N (2016) Clonal expansion of Escherichia coli ST38 carrying a chromosomally integrated OXA-48 carbapenemase gene. J Med Microbiol 65:538–546CrossRef

11.

Poirel L, Bonnin RA, Nordmann P (2012) Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob Agents Chemother 56:559–562CrossRef

12.

Potron A, Poirel L, Dortet L, Nordmann P (2016) Characterization of OXA-244, a chromosomally-encoded OXA-48-like β-lactamase from Escherichia coli. Int J Antimicrob Agents 47:102–103CrossRef

13.

Masseron A, Poirel L, Falgenhauer L, Imirzalioglu C, Kessler J, Chakraborty T, Nordmann P (2020) Ongoing dissemination of OXA-244 carbapenemase-producing Escherichia coli in Switzerland and their detection. Diagn Microbiol Infect Dis 97(3):115059CrossRef

14.

EUCAST. Clinical breakpoint table v.12.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf. Accessed 12 June 2022

15.

Poirel L, Walsh TR, Cuvillier V, Nordmann P (2011) Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70:119–123. https://doi.org/10.1016/j.diagmicrobio.2010.12.002CrossRefPubMed

16.

Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O et al (2012) Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 67:2640–2644CrossRef

17.

Seeman T (2014) Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069CrossRef

18.

Treangen TJ, Ondov BD, Koren S, Phillippy AM (2014) The harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes. Genome Biol 15:524CrossRef

19.

Wick RR, Judd LM, Gorrie CL, Holt KE (2017) Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595CrossRef

20.

Darling AE, Mau B, Perna NT (2010) Progressive Mauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS ONE 5:e11147CrossRef

21.

Findlay J, Hopkins KL, Loy L, Doumith M, Meunier D, Hill R, Pike R, Mustafa N, Livermore DM, Woodford N (2017) OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014. J Antimicrob Chemother 72(5):1340–1349CrossRef

22.

Liu Y-F, Yan J-J, Ko W-C, Tsai S-H, Wu J-J (2008) Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan. J Antimicrob Chemother 61:1020–1023CrossRef

23.

Sato T, Ito A, Ishioka Y, Matsumoto S, Rokushima M, Kazmierczak KM, Hackel M, Sahm DF, Yamano Y (2020) Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study. J Antimicrob Chemother 2:dlaa081

24.

Poirel L, Potron A, Nordmann P (2012) OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597–1606CrossRef

25.

Hendrickx AP, Landman F, de Haan A, Witteveen S, van Santen-Verheuve MG, Schouls LM (2021) blaOXA-48-like genome architecture among carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the Netherlands. Microb Genom 7:000512

Title: Molecular analysis of OXA-48-producing Escherichia coli in Switzerland from 2019 to 2020
Authors: Jacqueline Findlay
Vincent Perreten
Laurent Poirel
Patrice Nordmann
Publication date: 14-09-2022
Publisher: Springer Berlin Heidelberg
Keywords: Escherichia Coli
Carbapenem Antibiotic
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2022
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-022-04493-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2022

A longitudinal study of Candida bloodstream infections in a Japanese university hospital: species distribution, drug susceptibility, clinical features, and mortality predictors

Comparison between culture-positive and culture-negative septic shock in patients in the emergency department

Characteristics of endovascular pneumococcal infections; a decade of nationwide surveillance study

Determinants and outcomes of bloodstream infections related to obesity

Racemose neurocysticercosis simulating tuberculous meningitis

Ancient DNA confirmation of lepromatous leprosy in a skeleton with concurrent osteosarcoma, excavated from the leprosarium of St. Mary Magdalen in Winchester, Hants., UK

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials